Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.
About Artivion, Inc. (NYSE: AORT)
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a prominent medical device company dedicated to developing elegant and straightforward solutions addressing the complex challenges faced by cardiac and vascular surgeons in treating aortic diseases. The company offers a wide array of aortic-centric products, including aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, distributed in over 100 countries worldwide.
Recent Achievements and Financial Performance:
- For the third quarter of 2023, Artivion reported revenues of $87.9 million, marking a 14% increase year-over-year, with notable growth in aortic stent grafts and On-X mechanical heart valves.
- Completed enrollment in the PERSEVERE clinical trial, targeting PMA approval for the AMDS Hybrid Prosthesis by 2025, showcasing significant reductions in all-cause mortality and major adverse events.
- Announced a comprehensive $350 million non-dilutive credit agreement to address debt maturities and further optimize the capital structure, highlighting the company's strategic growth initiatives.
Product Innovation and Clinical Trials:
- The On-X Aortic Heart Valve Low INR post-market study demonstrated superior patient outcomes, significantly reducing major bleeding events compared to historic controls.
- Artivion's product portfolio includes innovative solutions like the AMDS Hybrid Prosthesis, aimed at improving outcomes for patients with acute DeBakey Type I aortic dissections.
With a strong focus on clinical efficacy and market expansion, Artivion continues to be a pivotal player in the cardiac and vascular surgery market, striving to deliver life-saving products and technologies that improve patient outcomes.
Artivion, Inc. (NYSE: AORT) reported strong first quarter 2024 financial results with revenue of $97.4 million, an increase of 17% on a GAAP basis. Net income was $7.5 million, and non-GAAP adjusted EBITDA increased by 60%. The company revised its FY24 revenue guidance to 9-12% growth. The On-X aortic valve post-market clinical study showed promising results, lowering the risk of major bleeding by 87%. Artivion raised the lower end of its revenue guidance for 2024 and expects non-GAAP adjusted EBITDA to increase by 26-34% compared to 2023.
Artivion, Inc. (NYSE: AORT) announced new clinical data for On-X Aortic Heart Valve and AMDS at the 104th AATS Annual Meeting. 5-year real-world safety and efficacy data from On-X Aortic Valve show better patient outcomes than predicted. AMDS PERSEVERE Trial data demonstrate positive aortic remodeling outcomes. On-X Aortic Valve remains safe with low-dose warfarin. AMDS prevents DANE tears and induces positive aortic remodeling.
FAQ
What is the current stock price of Artivion (AORT)?
What is the market cap of Artivion (AORT)?
What products does Artivion, Inc. offer?
Where is Artivion, Inc. headquartered?
What are some recent clinical achievements of Artivion?
What was Artivion's revenue growth in the third quarter of 2023?
How is Artivion addressing its debt maturities?
In how many countries does Artivion market its products?
What is the focus of Artivion's clinical trials?
What are the key products in Artivion's portfolio?
What are the benefits of the On-X Aortic Heart Valve?
When does Artivion expect to achieve PMA approval for the AMDS Hybrid Prosthesis?
